


RESEARCH

Open Access



Cardiac MRI-based right-to-left ventricular blood pool T2 relaxation times ratio correlates with exercise capacity in patients with chronic heart failure

Moritz C. Halfmann^{1,2}, Lukas Müller¹, Urs von Henning³, Roman Kloeckner^{1,4}, Theresia Schöler¹, Karl-Friedrich Kreitner¹, Christoph Düber¹, Philip Wenzel^{2,3}, Akos Varga-Szemes⁵, Sebastian Göbel^{3,6†} and Tilman Emrich^{1,2*†} 

Abstract

Background MRI T2 mapping has been proven to be sensitive to the level of blood oxygenation. We hypothesized that impaired exercise capacity in chronic heart failure is associated with a greater difference between right (RV) to left ventricular (LV) blood pool T2 relaxation times due to a higher level of peripheral blood desaturation, compared to patients with preserved exercise capacity and to healthy controls.

Methods Patients with chronic heart failure ($n = 70$) who had undergone both cardiac MRI (CMR) and a 6-min walk test (6MWT) were retrospectively identified. Propensity score matched healthy individuals ($n = 35$) served as control group. CMR analyses included cine acquisitions and T2 mapping to obtain blood pool T2 relaxation times of the RV and LV. Following common practice, age- and gender-adjusted nominal distances and respective percentiles were calculated for the 6MWT. The relationship between the RV/LV T2 blood pool ratio and the results from 6MWT were evaluated by Spearman's correlation coefficients and regression analyses. Inter-group differences were assessed by independent t-tests and univariate analysis of variance.

Results The RV/LV T2 ratio moderately correlated with the percentiles of nominal distances in the 6MWT ($r = 0.66$) while ejection fraction, end-diastolic and end-systolic volumes showed no correlation ($r = 0.09, 0.07$ and -0.01 , respectively). In addition, there were significant differences in the RV/LV T2 ratio between patients with and without significant post-exercise dyspnea ($p = 0.001$). Regression analyses showed that RV/LV T2 ratio was an independent predictor of the distance walked and the presence of post-exercise dyspnea ($p < 0.001$).

Conclusion The proposed RV/LV T2 ratio, obtained by two simple measurements on a routinely acquired four-chamber T2 map, was superior to established parameters of cardiac function to predict exercise capacity and the presence of post-exercise dyspnea in patients with chronic heart failure.

Keywords Heart failure, T2 mapping, Exercise capacity

[†]Sebastian Göbel and Tilman Emrich contributed equally to this work.

*Correspondence:

Tilman Emrich

tilman.emrich@unimedizin-mainz.de

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Heart failure (HF) is estimated to affect approximately 26 million people worldwide with prevalence steadily increasing due to an aging society [1–3]. Despite the overall improving prognosis, its 5-year mortality remains high and is characterized by poor quality of life [4]. Hence, there is a great scientific interest into HF, with the US National Library of Medicine listing over a thousand currently active studies on the topic. Besides typical endpoints including major adverse cardiac events (MACE), numerous surrogate parameters have been developed and are under constant re-evaluation.

One of those, the 6-min walking test (6MWT), a simple walking exercise, was first proposed in 1985 and since has been rigorously validated in clinical and scientific contexts [5–10]. The 6MWT has been shown to correlate with prognosis, therefore it got anchored in international HF guidelines and has evolved as the gold standard for the validation of new tests on functional capacity of patients [4, 11, 12].

Cardiac MRI (CMR) has a class I recommendation for the characterization of myocardial tissue and ventricular function according to the joint recommendations by the Society for Cardiovascular Magnetic Resonance (SCMR) and the European Association for Cardiovascular Imaging (EACVI) as well as the guidelines by the European Society of Cardiology (ESC) [12, 13].

In addition, the current clinical recommendations by the SCMR state that parametric mapping provides incremental value in the workup of patients with heart failure [13]. Specifically, T2 mapping allows for voxel-wise quantification of relaxation times and is primarily used to estimate myocardial oedema [14]. When this technique is applied to the blood pool, paramagnetic effects of deoxygenated haemoglobin compared to diamagnetic oxygenated haemoglobin can lead to a dephasing of spins within the erythrocytes [15, 16]. This in turn causes the shift of water protons by means of diffusion along local field gradients and thus results in a correlation of blood pool T2 relaxation times with levels of blood oxygenation [15–18].

Based on this mechanism, we hypothesized that impaired exercise capacity in HF is associated with a greater difference between right (RV) to left ventricular (LV) blood pool T2 relaxation times due to a higher level of peripheral blood desaturation, compared to patients with preserved exercise capacity and to healthy controls (HC). Thus, the aim of this study was to correlate the RV/LV T2 ratio with functional exercise capacity in patients with chronic HF who had previously undergone both CMR and 6MWT.

Methods

Study population

The local ethics committee approved the protocol of this retrospective study with a waiver for informed consent [reference number 837.196.13 (8881-F)].

A total of 271 patients who underwent CMR in 2021 were screened for the following inclusion criteria: (1) presence of chronic HF according to current guidelines [12]; (2) complete CMR including T2 mapping without severe artefacts; and (3) successfully performed 6MWT. After survey, 142 patients were excluded for the absence of HF, lung disease as the primary cause of symptoms or for being bed-ridden and therefore unable to complete the 6MWT.

Image quality assessment was performed by 2 independent observers (T.E. and M.C.H.) with 13 and 5 years of experience in the field, respectively. A third observer (A.V.S., 15 years of experience) mediated disagreement. The quality assessment was conducted based on the protocol validated by Klinker et al. within the European CMR registry [19]. Image slice thickness (8 mm) and interslice gap (2 mm) as well as the angulation of the image stacks were defined by institutional standard operating procedures. Failure to adhere to these in-house guidelines or incomplete LV-coverage resulted in the exclusion of the patient study. In addition, shortened study protocols without T2 mapping (i.e. due to limited breath-hold capabilities of the patient) were also excluded from the study. The remaining studies were evaluated for the presence and extent of the following artifacts: wrap around, respiratory/cardiac ghosting, image blurring/mis-triggering, metallic artifacts, shimmering artifacts and signal loss. In total, this led to the exclusion of an additional 59 patients due to incomplete or insufficient quality of CMR, resulting in a total of 70 patients who were included in the study (Fig. 1).

Additionally, 35 propensity score matched HC, who had previously participated in a prospective study to establish institutional CMR reference values, were included in this study. Propensity score matching was performed based on factors that are known to influence 6MWT including age, sex, weight, and height.

Demographic parameters, results from the 6MWT, objective lung function analysis results, and HF symptoms as rated on the New York Heart Association (NYHA) scale were derived from the electronic patient records.

Cardiac magnetic resonance imaging

All subjects underwent CMR (Software version XA30, Magnetom Prisma[®], Siemens Healthineers, Erlangen, Germany) at 3 Tesla (T). Short- and long-axis views




Fig. 1 Study flowchart

of standard balanced steady-state free precession cine acquisitions, T1 and T2 maps in short-axis views and four-chamber views were included among other routine sequences in a comprehensive clinical protocol. For T2 mapping, a commercially available sequence with 3 preparation pulses (0/30/55 ms) and a 3-heart-beat recovery period was used. All maps were acquired in the diastolic phase. Additional pulse sequence parameters can be found in Table 1.

End-diastolic (EDV) and end-systolic (ESV) volumes, ejection fraction (EF), and cardiac output index (CI) were calculated for both ventricles by semi-automatically drawn endocardial contours on the short-axis stack, using all three long-axis views as references. Subsequently, all volumes were indexed to body surface area (BSA).

For T2 mapping analysis, the source data was carefully reviewed to exclude flow artefacts. Subsequently, two circular regions of interest (ROI) with a minimum size of 1.5 cm² were placed in artefact free areas of the RV and LV blood pool, and the mean relaxation times were recorded (Fig. 2).

Table 1 Key CMR pulse sequence parameters for cine imaging and T2 mapping

	Cine	T2 mapping
Sequence type	bSSFP cine	T2 prepared bSSFP
ECG gating	Retrospective	Retrospective
Repetition time (ms)	3.88	3.15
Echo time (ms)	1.42	1.32
Field of view (mm)	360	360
Phases/cardiac cycle	25	n/a
Slice thickness (mm)	8.0	8.0
Flip angle (°)	60	12
Voxel size (mm ³)	1.5 × 1.5 × 8.0	1.9 × 1.9 × 8.0
Bandwidth (Hz/pixel)	930	1185

bSSFP balanced steady-state free precession, ECG electrocardiogram

Midventricular short-axis slices of native and post-contrast maps were semi-automatically segmented with a 25% endo- and epicardial offset margin. Together with haematocrit values, these were then used to calculate extracellular volume fraction (ECV). Quantitative assessment of late gadolinium enhancement (LGE) was performed using the semi-automated 5-standard deviation (SD) method on basal, midventricular and apical short-axis slices on phase-sensitive inversion recovery (PSIR) sequences acquired 10 min after administration of 0.2 mmol/kg gadoteric acid, as recommended by the SCMR [20]. Using the quantified amount of LGE, the myocardial scar burden was calculated as a percentage of myocardial mass.

6-min walking test

A trained nurse performed the 6MWT according to international guidelines [21, 22]. Prior to walking, the patient’s weight and height were noted. In addition, baseline systolic blood pressure (RR_{sys}), heart rate (HR) and peripheral capillary oxygen saturation (SpO₂) were measured. Patients were then instructed to walk as fast as possible on a marked course without changes of direction for six minutes. Changes in speed and breaks were allowed. After six minutes, the distance reached was recorded and post-exercise parameters were measured (RR_{sys}, HR, and SpO₂). In addition, the patient was asked to subjectively rate the level of dyspnoea on a modified Borg scale from 0 to 10. Patients with a subjective rating of 4 (“somewhat severe”) or higher were considered as having significant post-exercise dyspnoea in further analysis. As common practice, age and gender adjusted nominal distances and respective percentiles were calculated using the established formula by Troosters et al. [23].




Fig. 2 ROI placement in the RV and LV blood pool in T2 maps of a 62-year-old healthy man (left), a 67-year-old woman with HF (middle), and a 66-year-old man with HF (right). ROI region of interest, RV right ventricle, LV left ventricle, HF heart failure

Statistical analysis

Statistical analysis was performed using SPSS version 23 (IBM Corporation, Armonk, New York, USA). All data were tested for normal distribution using the Kolmogorov–Smirnov test and were subsequently either reported as mean \pm standard deviation or median with an interquartile range. Categorical data were reported as absolute frequencies and proportions.

Comparisons between groups and sub-groups were evaluated using independent t-tests or univariate analysis of variance (ANOVA), where appropriate. Correlations between distances and the RV/LV T2 ratio were assessed using Spearman's correlation coefficient. Univariate and multivariate linear regressions with block enter method and respective hazard-ratios were used to investigate predictors of the distance walked in the 6MWT. For multivariate regression analysis, variance inflation factors were calculated to test for multicollinearity. Factors of 5 or lower were considered acceptable. In addition, a binary logistic regression analysis was used to determine predictors for post exercise dyspnoea. In this retrospective study, statistical power for both the comparisons between cohorts and sub-cohorts as well as the regression models was assessed using a dedicated freeware tool (G*Power v3.1, <https://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower> [24]). A p-value < 0.05 was considered significant.

For reproducibility analysis, intra- and inter-reader agreement were assessed by intraclass correlation coefficients. In addition, agreement between different methods of ROI placement was evaluated by Bland–Altman analysis and coefficient of variance determination.

Results

Study participants

The mean age in the patient cohort was 60 ± 15 years with 18 (26%) women while in HC the mean age was 55 ± 11 years with 14 (40%) women. Electronic patient records revealed that 39 (56%) of patients had never smoked, 17 (24%) were past-smokers and 14 (20%) were actively smoking. Despite matching efforts, the HF group had significantly higher body mass index (BMI) (27.4 ± 5.7 vs. 24.6 ± 4.7 kg/m², $p = 0.01$).

Cardiac magnetic resonance imaging

During image quality assessment, the observers were in disagreement in a total of 3 cases (observer 1: 59 exclusions, observer 2: 60 exclusions). Together with the mediation observer, a consensus was reached resulting in the following distribution of reasons for exclusion: Failure to adhere to in-house guidelines or incomplete LV-coverage ($n = 7$; 12% of excluded studies), shortened study protocol without T2 mapping ($n = 36$; 61%), wrap around artifacts ($n = 1$, 2%), respiratory/cardiac ghosting ($n = 2$, 3%), image blurring/mis-triggering ($n = 8$, 14%) metallic artifacts ($n = 2$, 3%), shimming artifacts/signal loss (“off-resonance”; $n = 3$, 5%).

Biventricular functional CMR analysis showed significant differences between HF patients and HC for all parameters except for CI (3.1 ± 1.3 vs. 3.0 ± 0.7 , $p = 0.994$) and RVEDVi (93.4 ± 30.7 vs. 87.5 ± 15.5 , $p = 0.192$). Additionally, the patient population was stratified by aetiology of HF as well as the categories of HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF). This information, along further baseline characteristics, can be found in Table 2. None of the CMR parameters differed significantly between patients referred for CMR

Table 2 Baseline characteristics

	Patients with HF _r EF (n = 40)	Patients with HF _m rEF (n = 8)	Patients with HF _p EF (n = 22)	Healthy controls (n = 35)
Demographics				
Females (%)	11 (28)	0 (0)	7 (32)	14 (40)
Age (years ± SD)	63 ± 13	59 ± 11	56 ± 17	55 ± 11
BMI (kg/m ² ± SD)	27.0 ± 6.0	23.3 ± 2.5	29.7 ± 5.2	24.6 ± 4.7
BSA (m ² ± SD)	1.94 ± 0.27	1.89 ± 0.18	2.03 ± 0.18	1.89 ± 0.24
Active smokers (%)	8 (20)	2 (25)	4 (18)	0 (0)
BNP (pg/ml)	924 ± 2412 ^a	871 ± 1233 ^a	142 ± 174 ^a	n/a
NYHA class				
I (%)	11 (28)	2 (25)	8 (36)	n/a
II (%)	11 (28)	5 (63)	9 (41)	n/a
III (%)	17 (42)	1 (12)	4 (18)	n/a
IV (%)	1 (2)	0 (0)	1 (5)	n/a
Aetiology of HF				
DCM (%)	19 (48)	2 (25)	2 (9)	n/a
HCM (%)	3 (8)	0 (0)	4 (18)	n/a
ICM (%)	10 (25)	1 (13)	4 (18)	n/a
Inflammatory (%)	1 (2)	2 (25)	4 (18)	n/a
Other (non-ICMP) (%)	7 (17)	3 (37)	8 (36)	n/a
CMR				
LVEDVi (ml/m ² ± SD)	136.1 ± 49.7	117.6 ± 18.6	87.4 ± 21.2	76.6 ± 11.0
LVESVi (ml/m ² ± SD)	103.3 ± 47.4	69.8 ± 20.0	35.0 ± 11.3	29.3 ± 6.4
LVMi (g/m ² ± SD)	76.0 ± 24.1	83.6 ± 23.3	62.3 ± 24.5	57.2 ± 8.9
LVCI (ml/min/m ² ± SD)	2.5 ± 1.0	3.5 ± 1.1	3.9 ± 1.3	3.1 ± 0.7
LVEF (% ± SD)	25 ± 8.7	43.3 ± 2.6	60.1 ± 8.1	61.6 ± 5.6
RVEDVi (ml/m ²)	86.5 ± 46.1 ^a	104.9 ± 11.2 ^a	85.8 ± 11.5 ^a	87.5 ± 15.5 ^a
RVESVi (ml/m ²)	63.9 ± 31.4 ^a	70.8 ± 33.3 ^a	49.8 ± 5.2 ^a	44.7 ± 12.6 ^a
RVCI (ml/min/m ² ± SD)	1.9 ± 1.0	2.1 ± 0.8	2.6 ± 1.0	2.8 ± 0.7
RVEF (%)	26.5 ± 11.7 ^a	32.1 ± 10.1 ^a	42.3 ± 8.1 ^a	49.3 ± 8.4
Native T1 (ms ± SD)	1290 ± 57 ^a	1300 ± 55	1256 ± 82	1188 ± 46
ECV (% ± SD)	31.5 ± 6.3	32.6 ± 10.1	27.7 ± 5.0	24.3 ± 2.2
Scar burden (% ± SD)	6.5 ± 6.5	5.9 ± 14.6 ^a	6.7 ± 6.6	0.0 ± 0.0
RV/LV T2 ratio (± SD)	0.50 ± 0.11	0.50 ± 0.10	0.54 ± 0.14	0.74 ± 0.05

HF_rEF heart failure with reduced ejection fraction, HF_mrEF heart failure with mildly reduced ejection fraction, HF_pEF heart failure with preserved ejection fraction, BMI body mass index, BSA body surface area, BNP brain natriuretic peptide, NYHA New York Heart Association, HF heart failure, DCM dilated cardiomyopathy, HCM hypertrophic cardiomyopathy, ICMP ischemic cardiomyopathy, CMR cardiac magnetic resonance imaging, LV left ventricular, EDVi end-diastolic volume index, ESVi end-systolic volume index, CI cardiac output index, EF ejection fraction, LVMi left ventricular mass index, RV right ventricular, ECV extracellular volume fraction

^a Median ± interquartile range

in an acute setting such as first onset of HF symptoms (n = 28/70, 40%) and those undergoing a scheduled follow-up (n = 42/70, 60%) (all p > 0.100, Additional file 1: Table S1).

6-min walking test

All HF patients underwent 6MWT while HC did not. The mean distance reached by the HF patients was 425 ± 132 m and 19 (27%) patients rated their

post-exercise dyspnoea as 4 (“somewhat severe”) or higher on the modified Borg dyspnoea scale. There were no significant differences in baseline and post-exercise RR_{sys}, HR or SpO₂ between patients with and without relevant post-exercise dyspnoea. However, patients with dyspnoea reached significantly lower distances (314 ± 134 m vs. 466 ± 105 m, p < 0.001, Table 3).

Table 3 Baseline and post-exercise physiology

	Dyspnoea (n = 19)	No dyspnoea (n = 51)	p-value
LVEDVi (ml/m ² ± SD)	121.4 ± 55.0	117.7 ± 41.7	0.765
LVESVi (ml/m ² ± SD)	84.6 ± 56.2	68.3 ± 58.2 ^a	0.658 ^b
LVMi (g/m ² ± SD)	74.5 ± 24.4	70.0 ± 26.6 ^a	0.488 ^b
LVCI (ml/min/m ² ± SD)	2.8 ± 1.3	3.1 ± 1.3	0.319
LVEF (% ± SD)	35.9 ± 20.0	39.0 ± 17.2	0.531
RVEDVi (ml/m ² ± SD)	91.7 ± 40.7	89.0 ± 31.5 ^a	0.300 ^b
RVESVi (ml/m ² ± SD)	66.9 ± 36.8	55.5 ± 26.2 ^a	0.879 ^b
RVCI (ml/min/m ² ± SD)	1.9 ± 1.0	2.2 ± 1.1	0.223
RVEF (% ± SD)	27.8 ± 13.0	33.3 ± 13.3	0.130
Native T1 (ms ± SD)	1310 ± 84	1272 ± 64	0.105
ECV (% ± SD)	33.3 ± 8.6	29.1 ± 5.1	0.064
Scar burden (% ± IQR)	8.8 ± 5.0	4.2 ± 8.3 ^a	0.011
BNP (pg/ml)	1394 ± 3410 ^a	403 ± 697 ^a	0.225
RV/LV T2 ratio (± SD)	0.43 ± 0.11	0.54 ± 0.11	< 0.001
RR _{sys} (pre; mmHg ± SD)	120.5 ± 20.9	122.4 ± 22.2	0.757
RR _{sys} (post; mmHg ± SD)	137.1 ± 23.4	136.6 ± 22.9	0.931
HR (pre; 1/min ± SD)	79 ± 15	72 ± 14	0.075
HR (post; 1/min ± SD)	98 ± 18	93 ± 18	0.281
SpO ₂ (pre; % ± SD)	97 ± 2	97 ± 1	0.226
SpO ₂ (post; % ± SD)	97 ± 2	97 ± 2	0.799
Distance (m ± SD)	314 ± 134	466 ± 105	< 0.001

Post-exercise dyspnoea was subjectively judged based on a modified Borg dyspnoea scale and values ≥ 4 ("somewhat severe") were considered significant. Significant differences are highlighted in bold

LV left ventricular, EDVi end-diastolic volume index, ESVi end-systolic volume index, CI cardiac output index, EF ejection fraction, LVMi left ventricular mass index, RV right ventricular, ECV extracellular volume fraction, BNP brain natriuretic peptide, RR_{sys} systolic blood pressure, HR heart rate, SpO₂ peripheral capillary oxygen saturation

^a Median ± interquartile range

^b Derived from Mann-Whitney U test

Reproducibility analysis

There was excellent agreement between the RV/LV T2 ratio derived from the circular ROIs compared to planar ROIs encompassing the entire ventricular cavity ($r^2 = 0.89$, mean difference 0.0008 ± 0.040 , limits of agreement $-0.077, 0.077$). High rates of intrarater (ICC ≥ 0.93) as well as interrater reproducibility (ICC ≥ 0.96) were found for both methods. In addition, strong intraclass correlations were observed for measurements derived from basal, midventricular and apical short axis slices and four-chamber view long axis slices (all ICC ≥ 0.88).

Relationship between CMR and 6-min walking test

Median time between CMR and 6MWT was 62 ± 60 days. There was a moderate correlation ($r = 0.66$, $p < 0.001$) between the RV/LV T2 ratio and the percentile of the adjusted nominal distances (Fig. 3, left panel). Neither biventricular functional parameters nor T1 mapping showed significant correlations with the RV/LV T2 ratio (all $r < \pm 0.23$, $p > 0.05$) while the scar burden showed

a weak inverse correlation ($r = -0.29$, $p = 0.014$). In addition, there were significant differences in the RV/LV T2 ratio between patients with relevant post-exercise dyspnoea, none-to-insignificant dyspnoea and HC (0.43 ± 0.11 vs. 0.54 ± 0.11 vs. 0.74 ± 0.05 , all $p < 0.001$) (Fig. 3, right panel). There were no significant differences in LV volume indices or EF between patients with relevant post-exercise dyspnoea and those without.

In addition, there was a clear trend towards lower RV/LV T2 ratios in patients with higher NYHA classes with significant differences between all classes (0.60 ± 0.10 vs. 0.51 ± 0.10 vs. 0.44 ± 0.11 vs. 0.38 ± 0.12 , NYHA I–IV respectively) and HC (0.74 ± 0.05 , all $p < 0.001$) as well as NYHA I versus other classes ($p \leq 0.012$). There were no significant differences amongst patients with HFrEF (0.50 ± 0.11), HFmrEF (0.50 ± 0.10) and HFpEF (0.54 ± 0.14). Detailed results from the post-hoc subgroup analyses between types of HF and HC can be found in Additional file 1: Table S2.

Linear regression analyses showed that the RV/LV T2 ratio was the strongest tested predictor for the distance




Fig. 3 Correlation of the RV/LV T2 ratio with the percentiles of nominal distance (left) and boxplots showing the relationship of the RV/LV T2 ratio with post-exercise dyspnea (right). Brackets with asterisks mark significant differences. *RV* right ventricle, *LV* left ventricle

reached in the 6MWT among sex, age, NYHA class and CI (Fig. 4). Subsequent multivariate regression analysis including those five variables revealed that, among sex and age, the RV/LV T2 ratio remained an independent predictor for the distance reached in the 6MWT (Table 4). In the small subset of 10 (14%) patients, which had objective lung function analysis data available, univariate regression analysis revealed that pulmonary vital capacity, forced expiratory volume in 1 s, peak expiratory flow and pulmonary resistance were significant predictors of the distance walked in 6MWT. However, due to the small sample size, multivariate analysis was not feasible. Further, univariate logistic regression analyses revealed that the RV/LV T2 ratio was the only predictor for significant post-exercise dyspnoea ($\beta = -0.23$ [$-0.35, -0.10$], $p = 0.001$).

Discussion

This study investigated the relationship between RV-to-LV blood pool T2 relaxation times and exercise capacity in HF patients. The two main findings of this study can be summarized as follows: First, the RV/LV T2 ratio showed a moderate correlation with the distance patients with HF reached in the 6MWT. Second, age, sex and the RV/LV T2 ratio independently predicted the distance walked while the RV/LV T2 ratio was the only predictor of post-exercise dyspnoea.

HF is a major global health problem with increasing relevance in aging populations. All major cardiovascular societies have published HF guidelines with consistent recommendations for the diagnosis, treatment and risk stratification. In these, CMR has a central role for the

analysis of ventricular function and especially for tissue characterization [12, 25].

However, routine CMR only evaluates cardiac function at rest in a supine position, in which most patients with heart failure in NYHA stage lower than 3 are asymptomatic. This could also explain why, in agreement with previous literature, no significant correlations between the 6MWT and parameters of LV function at rest were found [9, 26, 27].

This diagnostic discrepancy between rest cardiac volumetry and symptom burden is especially relevant in patients whose day-to-day activity level approaches the maximal exercise capacity and in patients with preserved ejection fraction (HFpEF). In such patients, additional exercise test imaging has been shown to substantially improve the detection of HF [28–30], and therefore is adopted into current HF guidelines [31]. However, propositions such as treadmill exercise with subsequent CMR at maximum stress yield logistical difficulties in clinical reality and are therefore not routinely employed. In-scanner exercise using ergometers and real-time CMR sequences have been shown to accurately quantify volumes at rest and stress but require dedicated equipment, training of personnel, longer scan times and extensive post-processing capabilities [32–34]. The proposed RV/LV T2 ratio, on the other hand, utilizes data, which can be easily acquired during a routine scan. In addition, there is no need for complex post-processing capabilities, as ROIs can be placed in the ventricular blood pool either in-line on the scanner or afterwards using a simple digital imaging and communications in medicine (DICOM) viewer.

Oxygen take-up in the lungs and delivery to the tissues rely on haemoglobin. The relationship between oxygen




Fig. 4 Forest plots for the hazard ratios derived from univariate regression analyses for the prediction of the distance reached in the 6MWT. Significant predictors are highlighted in bold. BMI body mass index, BSA body surface area, NYHA New York Heart Association, EDVi end-diastolic volume index, ESVi end-systolic volume index, CI cardiac output index, EF ejection fraction, RV right ventricular, LV left ventricular, RR_{sys} systolic blood pressure, SpO₂ peripheral capillary oxygen saturation

and haemoglobin is commonly described through the oxygen dissociation curve. In brief, physiological compensation mechanisms either increase oxygen affinity to improve oxygen uptake (left shift) or decrease it to facilitate delivery to target tissues (right shift) [35, 36]. It is important to note that these shifts reciprocally impact each other. According to Fick’s law, another important factor for the efficiency of gaseous exchange is the surface available at the site of diffusion.

In HF patients, upregulation of the exchange surface (i.e. increased perfusion of the capillary beds) is limited and the oxygen dissociation curve therefore has to shift to the right. Hence, it can be hypothesized that blood

oxygenation levels at the end of the systemic circulation (i.e. in the RV) are lower due to increased oxygen delivery at the target tissues.

T2 mapping usually plays an important role for non-invasive tissue characterization [13]. In heart failure patients, it is used to detect myocardial oedema and chronic inflammation, especially in patients with dilated cardiomyopathy [12, 37, 38]. In this study, however, the known correlation of T2 relaxation times with blood oxygenation levels was used to investigate right-to-left ventricular differences in HF patients. Despite not directly quantifying oxygen saturation, the feasibility of this approach as a screening tool for right-to-left ventricular

Table 4 Regression analyses for distance walked in 6MWT

Variable	Univariate hazard ratio	p-value	Multivariate hazard ratio	p-value
Demographics				
Sex	-60.9 (-90.5, -31.3)	< 0.001	-49.4 (-69.8, -29.0)	< 0.001
Age	-58.5 (-85.2, -31.8)	< 0.001	-29.7 (-48.8, -10.6)	0.003
BMI	-4.0 (-34.5, 26.4)	0.792
BSA	20.7 (-10.7, 52.1)	0.193
Smoker status	20.2 (-8.0, 48.4)	0.157
NYHA class	-58.8 (-87.2, -30.5)	< 0.001	-0.5 (-29.5, 17.3)	0.603
BNP	-27.3 (-58.3, 3.8)	0.084
CMR				
LVEDVi (ml/m ²)	17.0 (-13.6, 47.6)	0.271
LVESVi (ml/m ²)	3.7 (-26.1, 33.4)	0.804
LVMi (g/m ²)	17.6 (-14.1, 49.3)	0.272
LVCI (ml/min/m ²)	43.4 (13.4, 73.3)	0.005	15.8 (-4.3, 36.0)	0.121
LVEF (%)	14.0 (-18.5, 46.4)	0.394
RVEDVi (ml/m ²)	-7.6 (-39.5, 24.3)	0.637
RVESVi (ml/m ²)	-4.6 (-36.6, 27.3)	0.773
RVCI (ml/min/m ²)	-6.1 (-38.1, 25.8)	0.702
RVEF (%)	-3.8 (-35.8, 28.1)	0.811
Native T1 (ms)	6.5 (-26.3, 39.4)	0.693
ECV (%)	22.4 (-11.1, 55.9)	0.186
Scar burden (%)	8.6 (-23.3, 40.5)	0.594
RV/LV T2 ratio	104.0 (73.8, 134.3)	< 0.001	84.8 (56.2, 113.4)	< 0.001
Baseline physiology				
RR _{sys} (mmHg)	1.2 (-30.3, 32.7)	0.940
HR (min ⁻¹)	-18.8 (-50.3, 12.6)	0.235
SpO ₂ (%)	19.4 (-12.2, 51.1)	0.225

6MWT 6-min walk test, BMI body mass index, BSA body surface area, NYHA New York Heart Association, BNP brain natriuretic peptide, CMR cardiac magnetic resonance imaging, LV left ventricular, EDVi end-diastolic volume index, ESVi end-systolic volume index, CI cardiac output index, EF ejection fraction, RV right ventricular, ECV extracellular volume fraction, RR_{sys} systolic blood pressure, SpO₂ peripheral capillary oxygen saturation

Significant predictors are highlighted in bold

shunts in patients with enlarged RV has already been demonstrated [17].

While T2-based non-invasive methods for direct quantification of blood oxygenation levels exist, they mostly require scanner-specific calibration, time-consuming examination protocols, or extensive post-processing [15, 39–42]. For instance, Varghese et al. proposed a method requiring the acquisition of four separate T2 maps, which were then fed into a Luz-Meiboom model for the estimation of oxygen saturation [41].

Despite not allowing direct quantification, the mean RV/LV T2 ratio was significantly different between HF patients exhibiting relevant post-exercise dyspnoea, none-to-insignificant dyspnoea and HC. Thus, additional physiological information, which could not be extracted from established parameters such as biventricular function or myocardial tissue characterization, was derived from a routine resting-state CMR. Furthermore, the RV/LV T2 ratio showed a stronger correlation to reduced

exercise capabilities of patients with heart failure than the relative myocardial scar burden while biventricular volumetric parameters showed no significant association with exercise capacities at all.

As this study had a cross-sectional design, causal relationship between the RV/LV T2 ratio and reduced exercise capacity will have to be determined in further studies. Similarly, prognostic implications of the reported data will have to be subject to further studies, despite the fact that the 6MWT is already an established independent predictor for prognosis. In a clinical setting, this could then lead to the RV/LV T2 ratio potentially being used to identify patients needing a closer follow-up and be evaluated as an easy-to-use tool to monitor therapeutic success.

Another interesting approach would be to apply the proposed method to exercise CMR in order to compare rest and exercise RV/LV T2 ratios, potentially making exercise reserve quantifiable by CMR.

Limitations

This is a single centre retrospective study performed with a single type of commercially available T2 mapping sequence. Despite this approach not needing a specifically tailored pulse sequence, results have to be validated at different field strengths and using different sequences. To facilitate this, a RV/LV ratio was chosen rather than RV T2 blood pool relaxation times alone. In previous work, the ratio approach has demonstrated convincing agreement at field strengths of 1.5 and 3 T [17]. In addition, the placement of the ROIs has to be performed very carefully and under consideration of the source data of the maps in order to avoid flow artefacts. In some cases, severe artefacts may limit the use of this technique in clinical practice and potential applications in exercise CMR. While feasibility of T1 mapping in exercise CMR has been shown, further studies will have to confirm the findings for T2 mapping before the proposed rest-to-stress RV/LV T2 ratio can be evaluated further. Third, the proposed RV/LV T2 ratio does not allow direct quantification of blood oxygenation and was not invasively verified at the time of CMR. In addition, during the time between CMR and 6MWT medical therapy could have influenced the results of the 6MWT and therefore biased the results. However, at the time of 6MWT none of the patients had a higher NYHA class than at time of CMR and no patients decompensated between examinations.

While this study demonstrated that the RV/LV T2 ratio is an independent predictor of exercise capacity in patients with HF, further studies will have to evaluate whether it is also an independent predictor of prognosis in these patients. Similarly, it is important to recognize pulmonary function as an additional factor on exercise function. In this retrospective study design, patients with known pulmonary disease as the leading cause of symptoms were therefore excluded. Nevertheless, in the small subset of patients with objective lung function data, it was shown that reduced pulmonary function is a significant predictor for less distance walked in the 6MWT. Unfortunately, the subgroup was too small for multivariate regression analysis and therefore, future prospective validation efforts will have to evaluate the interrelationship between the RV/LV T2 ratio and pulmonary function.

Furthermore, this study included patients with HF due to all aetiologies and also investigated patients with HFrEF, HFmrEF as well as HFpEF, resulting in a heterogeneous cohort of patients. Because of the size of the HFmrEF subgroup (n=8) and due to the fact that it only included males, results of the post-hoc analysis have to be interpreted cautiously as they might not be representative for this cohort. Further studies will have to investigate whether results are applicable for sub-cohorts

(i.e. HFpEF only). Finally, multiple equations for the calculation of age-, height-, weight-, and gender-adjusted nominal distances from 6MWT have been proposed and validated. The most commonly-used equations are by Troosters et al. [23] and Enright et al. [43]. This study is based on the former formula, however, as there is an almost perfect correlation between nominal distances of the two ($r=0.97$ for our data), the results are considered transferable.

Conclusion

The proposed RV/LV T2 ratio is a simple tool using routinely acquired data in the diagnostic work-up of HF patients. It independently predicts exercise capabilities and moderately correlates with the 6MWT. Further studies are needed to investigate its relationship to prognosis and its potential to aid in selecting patients who need a closer follow-up.

Abbreviations

6MWT	6-Minute walk test
ANOVA	Univariate analysis of variance
BMI	Body mass index
BNP	Brain natriuretic peptide
BSA	Body surface area
bSSFP	Balanced steady-state free precession
CI	Cardiac output index
CMR	Cardiac magnetic resonance imaging
EACVI	European Association for Cardiovascular Imaging
ECG	Electrocardiogram
ECV	Extracellular volume fraction
EDV	End-diastolic volume
EF	Ejection fraction
ESC	European Society of Cardiology
ESV	End-systolic volume
HC	Healthy controls
HF	Heart failure
HFmrEF	Heart failure with mildly reduced ejection fraction
HFpEF	Heart failure with preserved ejection fraction
HFrEF	Heart failure with reduced ejection fraction
HR	Heart rate
LGE	Late gadolinium enhancement
LV	Left ventricle
MACE	Major cardiac adverse events
MRI	Magnetic resonance imaging
NYHA	New York Heart Association
ROI	Region of interest
RR _{sys}	Systolic blood pressure
RV	Right ventricle
SCMR	Society for Cardiovascular Magnetic Resonance
SpO ₂	Peripheral capillary oxygen saturation
T	Tesla

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12968-023-00943-y>.

Additional file 1: Table S1. Comparison of CMR parameters between patient groups. **Table S2.** Results from post-hoc tests between types of HF and HC. **Table S3.** Multivariate regression analyses for distance walked in 6MWT. **Table S4.** Univariate regression analyses for distance walked in 6MWT.

Acknowledgements

SG and TE contributed equally to this work.

Author contributions

MCH analysed the CMR scans and had the lead role in writing the initial draft. LM and TS contributed statistical expertise as well as illustrations and were both major contributors in refining the initial draft. RK and AVS were major contributors in writing the manuscript. UH and PW examined the patients cardiologically and referred them for CMR as well as the 6MWT. KFK and CD provided resources and supervision from the radiological side and verified the interpretation of the CMR scans. SG and TE initiated the research project, designed the work and were both major contributors in refining the initial draft. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. PW is supported by a grant from the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (BMBF 01EO1503).

Availability of data and materials

The datasets analysed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The ethics committee of the state chamber of physicians in Rhineland-Palatinate, Germany approved the protocol of this retrospective study with a waiver for informed consent [reference number 837.196.13 (8881-F)].

Consent for publication

Not applicable.

Competing interests

The authors of this manuscript declare relationships with the following companies: AVS receives institutional research support and travel support from Siemens Healthineers and is consultant for Bayer and Elucid Bioimaging. TE has received a speaker fee and travel support from Siemens Healthineers. None of these companies supported this study and none of the other authors report a conflict of interest.

Author details

¹Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckst. 1, 55131 Mainz, Germany. ²German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Langenbeckst. 1, 55131 Mainz, Germany. ³Department of Cardiology, University Medical Center Mainz-Center of Cardiology, Johannes Gutenberg University, Langenbeckst.1, 55131 Mainz, Germany. ⁴Department for Interventional Radiology, University Hospital of Lübeck, Ratzeburger Allee 160, Lübeck, Germany. ⁵Division of Cardiovascular Imaging, Department of Radiology and Radiological Science, Medical University of South Carolina, Ashley River Tower, 5 Courtenay Drive, Charleston, SC 29425-2260, USA. ⁶Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckst. 1, 55131 Mainz, Germany.

Received: 17 October 2022 Accepted: 30 May 2023

Published online: 19 June 2023

References

- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139–596.
- Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. *ESC Heart Fail*. 2014;1:4–25.
- Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiu M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol*. 2014;63:1123–33.
- Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart*. 2007;93:1137–46.
- Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J*. 1985;132:919–23.
- Shah MR, Hasselblad V, Gheorghiu M, Adams KF Jr, Swedberg K, Califf RM, O'Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. *Am J Cardiol*. 2001;88:987–93.
- Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JG. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. *Eur Heart J*. 2005;26:778–93.
- Supervia M, Turk-Adawi K, Lopez-Jimenez F, Pesah E, Ding R, Britto RR, Bjarnason-Wehrens B, Derman W, Abreu A, Babu AS, Santos CA, Jong SK, Cuenza L, Yeo TJ, Scantlebury D, Andersen K, Gonzalez G, Giga V, Vulic D, Vataman E, Cliff J, Kouidi E, Yagci I, Kim C, Benaim B, Estany ER, Fernandez R, Radi B, Gaita D, Simon A, Chen SY, Roxburgh B, Martin JC, Maskhulia L, Burdiat G, Salmon R, Lomeli H, Sadeghi M, Sovova E, Hautala A, Tamuleviciute-Prasciene E, Ambrosetti M, Neubeck L, Asher E, Kemps H, Eysymontt Z, Farsky S, Hayward J, Prescott E, Dawkes S, Santibanez C, Zeballos C, Pavy B, Kiessling A, Sarrafzadegan N, Baer C, Thomas R, Hu D, Grace SL. Nature of cardiac rehabilitation around the globe. *EClinical-Medicine*. 2019;13:46–56.
- Faggiano P, D'Alòia A, Gualeni A, Brentana L, Dei Cas L. The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. *Eur J Heart Fail*. 2004;6:687–91.
- Ferreira JP, Duarte K, Graves TL, Zile MR, Abraham WT, Weaver FA, Lindendorf J, Zannad F. Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials. *J Am Coll Cardiol*. 2016;68:2690–707.
- Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol*. 2000;35:1245–55.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Mureretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42:3599–726.
- Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). *J Cardiovasc Magn Reson*. 2017;19:75.
- Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP. T2 quantification for improved detection of myocardial edema. *J Cardiovasc Magn Reson*. 2009;11:56.
- Wright GA, Hu BS, Macovski A. Estimating oxygen saturation of blood in vivo with MR imaging at 1.5 T. *J Magn Reson Imaging*. 1991;1:275–83.
- Thulborn KR, Waterton JC, Matthews PM, Radda GK. Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. *Biochim Biophys Acta*. 1982;714:265–70.

17. Emrich T, Bordonaro V, Schoepf UJ, Petrescu A, Young G, Halfmann M, Schoeler T, Decker J, Abidoye I, Emrich AL, Kreitner KF, Schmidt KH, Varga-Szemes A, Secinaro A. Right/left ventricular blood pool T2 ratio as an innovative cardiac MRI screening tool for the identification of left-to-right shunts in patients with right ventricular disease. *J Magn Reson Imaging*. 2021;55(5):1452–8.
18. Nagao M, Yamasaki Y, Kawanami S, Kamitani T, Sagiyama K, Higo T, Ide T, Takemura A, Ishizaki U, Fukushima K, Watanabe Y, Honda H. Quantification of myocardial oxygenation in heart failure using blood-oxygen-level-dependent T2* magnetic resonance imaging: comparison with cardiopulmonary exercise test. *Magn Reson Imaging*. 2017;39:138–43.
19. Klinke V, Muzzarelli S, Lauriers N, Locca D, Vincenti G, Monney P, Lu C, Nothnagel D, Pilz G, Lombardi M, van Rossum AC, Wagner A, Bruder O, Mahrholdt H, Schwitzer J. Quality assessment of cardiovascular magnetic resonance in the setting of the European CMR registry: description and validation of standardized criteria. *J Cardiovasc Magn Reson*. 2013;15:55.
20. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, Kim RJ, von Knobelsdorff-Brenkenhoff F, Kramer CM, Pennell DJ, Plein S, Nagel E. Standardized image interpretation and post-processing in cardiovascular magnetic resonance—2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): board of trustees task force on standardized post-processing. *J Cardiovasc Magn Reson*. 2020;22:19.
21. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166:111–7.
22. O’Keeffe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. *Heart*. 1998;80:377–82.
23. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. *Eur Respir J*. 1999;14:270–4.
24. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. *Behav Res Methods*. 2009;41:1149–60.
25. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. *J Am Coll Cardiol*. 2017;70(2017):776–803.
26. Opasich C, Pinna GD, Mazza A, Febo O, Riccardi R, Riccardi PG, Capomolla S, Forni G, Cobelli F, Tavazzi L. Six-minute walking performance in patients with moderate-to-severe heart failure: is it a useful indicator in clinical practice? *Eur Heart J*. 2001;22:488–96.
27. Zugck C, Krüger C, Dürr S, Gerber SH, Haunstätter A, Hornig K, Kübler W, Haass M. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? *Eur Heart J*. 2000;21:540–9.
28. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. *Circ Heart Fail*. 2010;3:588–95.
29. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. *Circulation*. 2017;135:825–38.
30. Craven TP, Tsao CW, La Gerche A, Simonetti OP, Greenwood JP. Exercise cardiovascular magnetic resonance: development, current utility and future applications. *J Cardiovasc Magn Reson*. 2020;22:65.
31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruijlope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37:2129–200.
32. Schnell F, Claessen G, La Gerche A, Claus P, Bogaert J, Delcroix M, Carré F, Heidbuchel H. Atrial volume and function during exercise in health and disease. *J Cardiovasc Magn Reson*. 2017;19:104.
33. La Gerche A, Claessen G, Van de Bruene A, Pattyn N, Van Cleemput J, Gewillig M, Bogaert J, Dymarkowski S, Claus P, Heidbuchel H. Cardiac MRI: a new gold standard for ventricular volume quantification during high-intensity exercise. *Circ Cardiovasc Imaging*. 2013;6:329–38.
34. Backhaus SJ, Lange T, George EF, Hellenkamp K, Gertz RJ, Billing M, Wachter R, Steinmetz M, Kutty S, Raaz U, Lotz J, Friede T, Uecker M, Hasenfuss G, Seidler T, Schuster A. Exercise stress real-time cardiac magnetic resonance imaging for noninvasive characterization of heart failure with preserved ejection fraction: the HFpEF-stress trial. *Circulation*. 2021;143:1484–98.
35. Boning D, Littschwager A, Hutler M, Beneke R, Staab D. Hemoglobin oxygen affinity in patients with cystic fibrosis. *PLoS ONE*. 2014;9: e97932.
36. Boning D, Schmidt WF. Role of haemoglobin oxygen affinity for oxygen uptake during exercise. *J Physiol*. 2020;598:3531–2.
37. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, de Waha S, Rommel KP, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Guterlet M. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-trial. *J Am Coll Cardiol*. 2016;67:1800–11.
38. Spieker M, Haberkorn S, Gastl M, Behm P, Katsianos S, Horn P, Jacoby C, Schnackenburg B, Reinecke P, Kelm M, Westenfeld R, Bönner F. Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. *J Cardiovasc Magn Reson*. 2017;19:38.
39. Golay X, Silvennoinen MJ, Zhou J, Clingman CS, Kauppinen RA, Pekar JJ, van Zijl PC. Measurement of tissue oxygen extraction ratios from venous blood T(2): increased precision and validation of principle. *Magn Reson Med*. 2001;46:282–91.
40. Nield LE, Qi XL, Valsangiacomo ER, Macgowan CK, Wright GA, Hornberger LK, Yoo SJ. In vivo MRI measurement of blood oxygen saturation in children with congenital heart disease. *Pediatr Radiol*. 2005;35:179–85.
41. Varghese J, Potter LC, LaFountain R, Pan X, Raman SV, Ahmad R, Simonetti OP. CMR-based blood oximetry via multi-parametric estimation using multiple T2 measurements. *J Cardiovasc Magn Reson*. 2017;19:88.
42. Wen Y, Weinsaft JW, Nguyen TD, Liu Z, Horn EM, Singh H, Kochav J, Eskreis-Winkler S, Deh K, Kim J, Prince MR, Wang Y, Spincemaille P. Free breathing three-dimensional cardiac quantitative susceptibility mapping for differential cardiac chamber blood oxygenation - initial validation in patients with cardiovascular disease inclusive of direct comparison to invasive catheterization. *J Cardiovasc Magn Reson*. 2019;21:70.
43. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. *Am J Respir Crit Care Med*. 1998;158:1384–7.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

